ERBB2 and breast cancer: Results showed a significant improved OS among patients after PMRT characterized by good prognostic markers such as HoR + and HER2‐ patients.24 Another study demonstrated that triple‐negative patients had the highest risk of locoregional recurrence and the least benefit from PMRT, while the greatest effect was seen among luminal‐A patients.25 These researches indicated that the largest RT benefit was shown in luminal‐type breast cancer.